Kost Gerald J, Ferguson William, Truong Anh-Thu, Hoe Jackie, Prom Daisy, Banpavichit Arirat, Kongpila Surin
a University of California, Davis, USA.
Expert Rev Mol Diagn. 2015;15(10):1245-59. doi: 10.1586/14737159.2015.1079776. Epub 2015 Sep 14.
Ultrahigh sensitivity and specificity assays that detect Ebola virus disease or other highly contagious and deadly diseases quickly and successfully upstream in Spatial Care Paths™ can stop outbreaks from escalating into devastating epidemics ravaging communities locally and countries globally. Even had the WHO and CDC responded more quickly and not misjudged the dissemination of Ebola in West Africa and other world regions, mobile rapid diagnostics were, and still are, not readily available for immediate and definitive diagnosis, a stunning strategic flaw that needs correcting worldwide. This article strategizes point-of-care testing for diagnosis, triage, monitoring, recovery and stopping outbreaks in the USA and other countries; reviews Ebola molecular diagnostics, summarizes USA FDA emergency use authorizations and documents why they should not be stop-gaps; and reduces community risk from internal and external infectious disease threats by enabling public health at points of need.
在空间护理路径™中,能够快速且成功地在早期检测出埃博拉病毒病或其他高度传染性和致命性疾病的超高灵敏度和特异性检测方法,可以阻止疫情升级为在当地社区和全球各国肆虐的毁灭性流行病。即便世界卫生组织和美国疾病控制与预防中心反应更快,没有误判埃博拉病毒在西非和世界其他地区的传播情况,但移动快速诊断工具过去没有、现在也仍然无法随时用于即时和明确诊断,这是一个令人震惊的战略缺陷,需要在全球范围内加以纠正。本文针对美国和其他国家的诊断、分诊、监测、康复及疫情防控制定了即时检测策略;回顾了埃博拉病毒分子诊断方法,总结了美国食品药品监督管理局的紧急使用授权,并阐述了为何这些授权不应只是权宜之计;通过在需求点实现公共卫生,降低社区面临的内部和外部传染病威胁风险。